10-K/A: Ekso Bionics Files Amended Annual Report
Annual Report Amendment
Ekso Bionics Holdings, Inc. has filed an amended annual report (Form 10-K/A) to include Part III information and updated certifications.
Summary
- This filing is an amendment (Amendment No. 1) to Ekso Bionics Holdings, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The amendment is being filed to provide Part III information, as a definitive proxy statement will not be filed within the required timeframe.
- Updated certifications from the Principal Executive Officer (Scott G. Davis) and Principal Financial Officer (Jerome Wong) are included, dated April 10, 2026.
- The filing does not contain updated financial statements and should be read in conjunction with the original Form 10-K filed on February 23, 2026.
- Information regarding directors, executive officers, executive compensation, security ownership, related party transactions, and principal accounting fees is detailed within Part III.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a procedural amendment to a previous report and does not contain new financial or operational information.
Future Outlook
No specific forward-looking statements or guidance are provided in this amendment, as it primarily addresses procedural and informational requirements.
Management Comments
- Scott G. Davis (Principal Executive Officer): "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
- Jerome Wong (Principal Financial Officer): "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
Industry Context
StockSavvy.ai notes that this amended filing is a procedural update for Ekso Bionics Holdings, Inc., focusing on corporate governance and executive disclosures rather than operational or financial performance, which is typical for 10-K amendments filed to meet specific SEC requirements.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Committees | Details on the responsibilities and members of the Audit Committee, Compensation Committee, and Nominating and Governance Committee are provided. | Throughout 2025 | Provides transparency into the oversight functions of the Board of Directors. |
| Code of Business Conduct and Ethics | The company has adopted a Code of Business Conduct and Ethics applicable to all directors, officers, and employees. | Ongoing | Establishes ethical standards and compliance guidelines for all personnel. |
| Risk Oversight | The Board of Directors oversees the risk management process, with specific committee responsibilities for financial reporting, compensation, and governance risks. | Ongoing | Ensures a structured approach to identifying and managing company risks. |
| Hedging and Insider Trading Policies | Policies are in place prohibiting employee hedging and governing insider trading. | Ongoing | Aims to prevent insider trading and mitigate risks associated with speculative trading by insiders. |
| Compensation Recovery Policy | A clawback policy is in place to recover incentive compensation in the event of an accounting restatement due to material noncompliance. | Effective October 2, 2023, as per Dodd-Frank Act | Aligns executive compensation with accurate financial reporting and compliance. |
Legal Proceedings
- No director or associate of a director is involved in any material proceeding as a party adverse to the Company or with a material interest adverse to the Company.
Related Party Transactions
- The company has a policy for reviewing related person transactions, with the Audit Committee responsible for approval, ratification, or disapproval.
- SEC rules require disclosure of transactions exceeding $120,000 where a related person has a material interest.
Stakeholder Impact
- Shareholders: The filing provides transparency on executive compensation, board composition, and corporate governance, which can influence investor confidence.
- Employees: Information on executive compensation and incentive plans may indirectly affect employee morale and alignment.
- Management: Details on compensation, severance agreements, and governance policies are relevant to executive roles and responsibilities.
Next Steps
- The company will file a definitive proxy statement at a later date.
- The company will continue to comply with SEC filing requirements.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year ended |
| 2026-02-23 | Original Form 10-K filing date |
| 2026-04-02 | As of date for outstanding shares |
| 2026-04-10 | Date of certifications |
Keywords
Ekso Bionics Holdings, 10-K/A, Annual Report, SEC Filing, Amendment, Executive Compensation, Corporate Governance, Certifications
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.